Last updated: August 1, 2026
Meclofenamate sodium is an NSAID used for pain and inflammatory conditions. Clinical development activity, FDA/regulatory status, and commercial projections depend on jurisdiction-specific approvals and sales channels, because meclofenamate sodium is not a single standardized “platform asset” with consistent global program branding across markets. A patent and regulatory roll-up is not possible from the current input, so market forecasts cannot be tied to a specific approved reference product, label, or dosing form.
What is the current clinical trials status for meclofenamate sodium?
Answer: No complete, current global clinical trial inventory can be produced from the information provided.
What clinical trial registries track meclofenamate sodium?
- ClinicalTrials.gov
- EU Clinical Trials Register
- WHO ICTRP aggregations
What endpoints are typically used in meclofenamate sodium trials?
- Pain intensity (VAS, NRS)
- Functional outcomes
- Inflammation markers
- Safety endpoints (GI, renal, cardiovascular)
Which trial phases are most common for NSAID repurposing of meclofenamate sodium?
- Phase 2 dose finding (analgesia and tolerability)
- Phase 3 comparative efficacy vs active NSAIDs (when pursued)
- Bioequivalence studies when reformulations are commercialized
When are major meclofenamate sodium trials expected to read out?
Answer: A schedule cannot be produced from the information provided.
What drives readout timing for NSAID programs?
- Enrollment rate and geographic distribution
- Dose arms and parallel safety monitoring
- Needed sample size for non-inferiority vs comparator NSAIDs
What typically affects FDA or EMA review timelines for NSAIDs?
- Completeness of safety database
- Quality of PK/BE data for reformulations
- Strength of clinical comparators to support label claims
How many active clinical studies involve meclofenamate sodium right now?
Answer: The number of active studies cannot be calculated from the information provided.
What trial categories would count as “active”?
- Recruiting
- Not yet recruiting
- Active, not recruiting
- Enrolling by invitation (depending on registry definitions)
What is the market size for meclofenamate sodium, and where is it sold?
Answer: Market size and sales geography cannot be quantified from the information provided.
What product form factors affect marketability for meclofenamate sodium?
- Oral solid (tablets/capsules)
- Topical or other delivery formats (if marketed locally)
- Combination products (if approved in certain territories)
How do local approvals shape commercial reach?
- Product name and salt form alignment (meclofenamate sodium vs alternative presentations)
- Patent and reimbursement status
- National formulary placement
How do NSAID competitors affect meclofenamate sodium pricing and uptake?
Answer: A competitor-by-competitor impact analysis cannot be produced from the information provided.
Which competitor classes typically displace older NSAIDs?
- COX-2 selective agents (where reimbursed)
- Newer topical NSAIDs
- Fixed-dose combinations
- Generic penetration post-patent expiry for originator NSAIDs
What matters most for channel pull-through
- Reimbursement tiers
- Prescriber familiarity
- Safety profile in high-risk populations
- Tender pricing and distribution agreements
What is the revenue projection for meclofenamate sodium through 2030 and 2036?
Answer: A numerical forecast cannot be produced from the information provided.
How do forecasts for mature NSAIDs usually get modeled?
- Unit growth from formulary penetration
- Price erosion from generic competition
- Switching driven by safety signals and guideline updates
- Uptake of reformulated or combination products
What assumptions typically anchor a 10-year NSAID forecast
- Share shifts among NSAID brands
- Sustainability of reimbursement
- Regulatory stability of the label and indications
What regulatory pathway applies to meclofenamate sodium in the US and EU?
Answer: Regulatory status cannot be determined from the information provided.
What filing types are most common for established NSAIDs
- ANDA for generics
- 505(b)(2) for label or formulation changes
- BE studies for reformulations
What label elements usually gate market growth
- Indication breadth
- Dosing convenience
- Safety warnings that affect prescribing behavior
What patent estate exists for meclofenamate sodium, and how strong is it?
Answer: A patent estate and strength assessment cannot be produced from the information provided.
What IP layers typically matter for NSAIDs
- Active ingredient patents (often older)
- Salt/crystal form patents
- Formulation patents
- Method-of-use patents for specific indications
- Process/manufacturing patents
Which litigation events typically change market access
- ANDA litigation (paragraph IV)
- Settlement agreements impacting generic timing
- Injunctions affecting launch calendars
What is the Orange Book status of meclofenamate sodium products?
Answer: Orange Book listing status cannot be provided from the information provided.
What Orange Book data would be required to answer
- Drug product active ingredient entries
- Applicant/labeler
- Patent numbers and expiration dates
- Exclusivity codes and periods
What generic entry risks exist for meclofenamate sodium?
Answer: Generic entry risk cannot be assessed from the information provided.
What would typically drive generic entry
- Patent expiry timing
- Exclusivity expiration
- Ongoing litigation posture
- Local regulatory approvals and bioequivalence requirements
How does meclofenamate sodium compare with other NSAIDs on safety and efficacy?
Answer: A comparative evidence synthesis cannot be produced from the information provided.
What safety signals drive clinician switching among NSAIDs
- GI tolerability
- Renal risk
- Cardiovascular risk
- Elderly and comorbidity-specific warnings
What efficacy comparisons usually include in trials
- Total pain relief over defined windows
- Time to meaningful pain reduction
- Responder rates
Key commercial scenarios for meclofenamate sodium (base, upside, downside)
Answer: Scenario forecasts cannot be quantified from the information provided.
Base-case scenario (typical for mature NSAIDs)
- Flat to low single-digit unit growth
- Ongoing price erosion from generics
- Limited label expansion
Upside scenario (typical catalysts)
- New indication or improved formulation reduces dosing burden
- Reimbursement improves in key markets
- Safety positioning strengthens share vs displaced competitors
Downside scenario (typical risks)
- Negative safety signals or guideline de-emphasis
- Reimbursement cuts or tender pricing pressure
- Loss of supply or manufacturing constraints
Key Takeaways
- No complete clinical trials update, market size, regulatory status, or forecast can be generated from the information provided.
- A defensible assessment requires an anchored basis: specific approved product, jurisdiction(s), formulation strength, and a registry-level program inventory.
- Once anchored, a full pipeline calendar, Orange Book/regulatory mapping, and financial forecast model can be constructed around patent expiry, exclusivity, and generic entry timing.
FAQs
- Is meclofenamate sodium approved in the US and which dosage forms are available?
- Are there any ongoing Phase 2 or Phase 3 clinical trials specifically for meclofenamate sodium?
- Does meclofenamate sodium have any FDA Orange Book listed patents or exclusivity periods?
- What are the main generic risks for meclofenamate sodium in major markets?
- How do topical or reformulated versions of meclofenamate sodium change market access and uptake?
References
- ClinicalTrials.gov. (n.d.). Database entries for meclofenamate sodium. https://clinicaltrials.gov
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- EMA. (n.d.). European Medicines Agency product and clinical trial databases. https://www.ema.europa.eu
